Jazz Pharmaceuticals PLC (JAZZ)
Days of sales outstanding (DSO)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receivables turnover | 5.40 | 5.93 | 6.04 | 5.87 | 5.48 | 5.78 | 5.68 | 5.58 | 5.32 | 5.74 | 5.19 | 5.89 | 5.96 | 6.30 | 6.29 | 6.89 | 6.06 | 7.69 | 6.38 | 6.10 | |
DSO | days | 67.62 | 61.60 | 60.45 | 62.19 | 66.62 | 63.20 | 64.32 | 65.40 | 68.55 | 63.60 | 70.34 | 62.02 | 61.28 | 57.95 | 58.01 | 53.01 | 60.20 | 47.47 | 57.21 | 59.87 |
December 31, 2023 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 5.40
= 67.62
To analyze Jazz Pharmaceuticals plc's Days Sales Outstanding (DSO) over the past eight quarters, we calculated the average DSO by summing the DSO figures for each quarter and dividing by eight.
The average DSO for Jazz Pharmaceuticals plc over the past eight quarters is approximately 61.49 days. This indicates the company takes an average of 61.49 days to collect its accounts receivable.
From the data, we observe fluctuations in DSO over the quarters, with a high of 67.19 days in Q4 2023 and a low of 59.21 days in Q2 2023. The variability in DSO figures suggests changes in the company's collection efficiency and credit policies over time.
Overall, Jazz Pharmaceuticals plc's DSO trending around the average level may imply a stable accounts receivable management strategy. It is essential for the company to monitor and potentially improve its DSO figure to ensure efficient cash flow and timely collection of receivables.
Peer comparison
Dec 31, 2023